Holen Sie sich die Stockscreener-App
14.19
2.81%
-0.41
Handel nachbörslich:
14.18
-0.010
-0.07%
Atrium Therapeutics Inc Aktie (RNA) Neueste Nachrichten
Wall Street Money Is Leaving Just As Atrium’s (RNA) Pipeline Turns Real - Yahoo Finance
Atrium Therapeutics to Participate in Upcoming Investor Conferences - PR Newswire
Atrium Therapeutics, Inc. (RNA) - DirectorsTalk Interviews
Can Atrium Therapeutics (RNA)’s $15 Million Milestone From Bristol-Myers Squibb (BMY) Validate its RNA Platform? - Yahoo Finance
Atrium Therapeutics, Inc. Share Price Live Today – NASDAQ:RNA Stock Price, Chart, News, History - Upstox
Atrium Therapeutics, Inc. (RNA) Stock Analysis: A Biotech Player with a Potential 89% Upside - DirectorsTalk Interviews
BRIEF-Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule - Dailyhunt
A new Atrium hire gets options on 11,000 shares and 5,500 restricted units - Stock Titan
Atrium (RNA) Momentum: Records a 1.68% Decrease to $13.48; Technical View: the Price Remains Bounded by the Supplied Support and Resistance in the Latest ReadingBreakaway Gap - vinanet.vn
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Atrium (RNA) Closing Snapshot: Closes 0.93% Lower at $12.84 in Latest Trading; Level Check: the Supplied Trading Band Runs From $12.20 to $13.48 in the Latest ReadingStop Loss Guidance - Vinanet
Atrium Therapeutics (RNA) Inches Higher: 0.93% Gain Reinforces Support ZoneDark Pool Sentiment - vinanet.vn
Atrium Therapeutics (RNA) Climbs 2.4% as Shares Hold Above Critical SupportCup and Handle - dars.gov.et
Atrium Therapeutics, Inc. (RNA) Stock Analysis: 94.70% Potential Upside Catches Investor Attention - DirectorsTalk Interviews
Atrium Therapeutics (RNA) Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts Investor SentimentDividend Earnings Report - vinanet.vn
Atrium Therapeutics (RNA) Jumps 4.14% to $12.84 as Buyers Defend Key SupportValue Area High - vinanet.vn
Atrium Therapeutics (RNA) Climbs 4.1% to $12.84 as Biotech Sentiment StrengthensLow Beta Factor - Vinanet
Atrium Therapeutics (RNA): RA Capital and affiliates report 0% beneficial ownership - Stock Titan
Aterian: Q2 Earnings Snapshot - AOL.com
Sessa Capital discloses 8.8% Atrium Therapeutics (RNA) ownership through managed funds - Stock Titan
T. Rowe Price Associates (RNA) discloses 8.6% Atrium Therapeutics ownership in 13G/A - Stock Titan
Atrium Therapeutics, Inc.: Financial Data Forecasts Estimates and Expectations | RNA | US04965N1046 - marketscreener.com
Atrium Therapeutics Q2 Net Loss Widens to $21.6 Million on Higher Spending - Minichart
Atrium Therapeutics Earns $15M BMS Milestone Payment, Advances Gene Therapy Candidate - Minichart
Form 8K Atrium Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Heart drug developer Atrium Therapeutics' Q2 loss widens as expenses rise - TradingView
Atrium Therapeutics Q2 Results: Sales beat 50%, EPS miss widens - scanx.trade
Atrium Therapeutics, Inc. Q2 2026: Revenue $3M, EPS $(1.18) — 10-Q Summary - TradingView
Atrium Therapeutics (RNA) grows collaboration revenue to $22.6M while scaling R&D spend - Stock Titan
Atrium Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
META_TITLE_QUOTE - Yahoo Finance
Atrium Therapeutics Reports Second Quarter 2026 Financial Results - KITV
Fierce Biotech Fundraising Tracker '26: InduPro assembles $77M; Vaderis nets $152M series B - Fierce Biotech
Atrium Therapeutics Earns $15M BMS Milestone - Contract Pharma
Atrium Therapeutics receives $15m milestone from Bristol Myers Squibb By Investing.com - Investing.com Nigeria
Atrium Therapeutics Earns Another $15 Million Milestone Payment From Bristol Myers Squibb - marketscreener.com
Atrium Therapeutics receives $15m milestone from Bristol Myers Squibb - Investing.com
Fate Therapeutics: Q2 Earnings Snapshot - AOL.com
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration - PR Newswire
Atrium Therapeutics (RNA) Sheds 0.8% to $12.17 as $11.56 Support LoomsSpring Pattern - dars.gov.et
Atrium Therapeutics (RNA) Holds Steady at $12.23 as Shares Trade Within Established RangeInsider Selling Alerts - vinanet.vn
Atrium Therapeutics, Inc. (RNA) Stock Analysis: Exploring a Potential 102.59% Upside in the Booming RNA Therapeutics Market - DirectorsTalk Interviews
H.C. Wainwright Initiates Atrium Therapeutics(RNA.US) With Buy Rating, Announces Target Price $25 - Moomoo
Actinium: Q2 Earnings Snapshot - AOL.com
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Sahm
Atrium Therapeutics (RNA) Climbs 1.99% to $11.77, Approaching Key Resistance at $12.36Volume Oscillator - dars.gov.et
Atrium Therapeutics, Inc. (RNA) Stock Analysis: A 120% Upside Potential Awaits Investors - DirectorsTalk Interviews
RNA Q1 2026 Earnings: Narrower-Than-Expected Loss Drives 2.5% Share UpswingReturn On Capital - Vinanet
RNA Q1 2026 Earnings: Narrower-than-expected loss fails to lift sharesForward Guidance Trends - vinanet.vn
BlackRock (RNA holder) discloses 6.6% Atrium Therapeutics stake in amended ownership filing - Stock Titan
Atrium Therapeutics, Inc. Revenue Breakdown – NASDAQ:RNA - tradingview.com
Atrium Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift StockPre-Announcement Alert - Vinanet
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Atrium Therapeutics (RNA): Flat Trading as Stock Hovers Near Key Support LevelsMonthly Profile - dars.gov.et
Wells Fargo Remains a Buy on Atrium Therapeutics, Inc. (RNA) - The Globe and Mail
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower-Than-Expected Loss as Pre-Commercial Spend Weighs on ResultsEnergy Earnings Report - dars.gov.et
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower-Than-Expected Loss Provides a Modest SurpriseLow Estimate Range - dars.gov.et
Wells Fargo Maintains Atrium Therapeutics(RNA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Atrium’s ATR-1072 gains IND clearance for PRKAG2 syndrome - BioWorld News
Atrium Therapeutics Receives FDA Clearance for ATR 1072, Launches First Clinical Trial Targeting PRKAG2 Syndrome - Minichart
FDA Clears Atrium Therapeutics' IND Application for Cardiomyopathy Drug - dicardiology.com
Atrium Therapeutics (Nasdaq: RNA) prepares Corventis PRKAG2 trial launch - Stock Titan
Atrium Therapeutics Secures FDA Clearance for ATR 1072 Trial - grafa.com
Atrium gets FDA clearance for PRKAG2 syndrome trial - Investing.com UK
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):